Loading organizations...
Loading organizations...
Biopharmaceutical company developing large-scale antibody therapeutics.
SAB Biotherapeutics has raised $37.4M across 3 funding rounds.
SAB Biotherapeutics has raised $37.4M in total across 3 funding rounds.
SAB Biotherapeutics has raised $37.4M in total across 3 funding rounds.
SAB Biotherapeutics's investors include Merck, South Dakota Equity Partners, National Institutes of Health.
SAB Biotherapeutics has raised $37.4M across 3 funding rounds. Most recently, it raised $14.0M Series B in July 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 17, 2020 | $14.0M Series B | Merck, South Dakota Equity Partners | |
| Dec 20, 2018 | $22.0M Series A | ||
| Sep 9, 2016 | $1.4M Grant | National Institutes of Health |